Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6599991 | 1.00 | NPSR1 (0.34) | NPSR1OPRK1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL6600000 | 1.00 | NPSR1 (0.34) | NPSR1OPRK1ALDH1A1TSHRHSD17B10 | |
| SCHEMBL6602540 | 0.94 | CYP2D6 (0.31) | ALDH1A1 | |
| SCHEMBL6602543 | 0.94 | CYP2D6 (0.31) | ALDH1A1 | |
| SCHEMBL6602547 | 0.94 | CYP2D6 (0.31) | ALDH1A1 | |
| SCHEMBL6601578 | 0.88 | ALDH1A1 (0.40) | NPSR1OPRK1ALDH1A1TSHR | |
| SCHEMBL6601584 | 0.88 | ALDH1A1 (0.40) | NPSR1OPRK1ALDH1A1TSHR | |
| SCHEMBL6601571 | 0.88 | ALDH1A1 (0.40) | NPSR1OPRK1ALDH1A1TSHR | |
| SCHEMBL6603388 | 0.87 | RAB9A (0.36) | ALDH1A1TSHR | |
| SCHEMBL6603393 | 0.87 | RAB9A (0.36) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794523-B2 | ANTICANCER AGENTS, ANTITUMOR AGENTS; LEUKEMIA | FLORIDA STATE UNIVERSITY | 2004-09-21 | — | — | US | disclosed |
| EP-0667772-B9 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | FLORIDA STATE UNIVERSITY | 2003-10-02 | — | — | US | disclosed |
| EP-0667772-B1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | UNIV FLORIDA STATE (US) | 2003-05-14 | — | — | EP | disclosed |
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | FLORIDA STATE UNIVERSITY | 2003-04-03 | — | — | US | disclosed |
| US-6521660-B2 | Anticancer, antitumor agents | FLORIDA STATE UNIVERSITY | 2003-02-18 | — | — | US | disclosed |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY | 2002-10-10 | — | — | US | disclosed |
| US-6335362-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS FOR LEUKEMIA | FLORIDA STATE UNIVERSITY | 2002-01-01 | — | — | US | disclosed |
| US-6018073-A | Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them | FLORIDA STATE UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5739362-A | ANTILEUKEMIA, ANTITUMOR AGENTS | FLORIDA STATE UNIVERSITY (US) | 1998-04-14 | — | — | US | disclosed |
| EP-0667772-A4 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | UNIV FLORIDA STATE (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0667772-A1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FLORIDA STATE UNIVERSITY (US) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010997-A1 | TAXANES HAVING AN ALKYL SUBSTITUTED SIDE-CHAIN AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FLORIDA STATE UNIVERSITY (US) | 1994-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065200-A1 | Anticancer agents, antitumor agents; leukemia | MCL1, BCL3, TOP2A | NPSR1 4199/4885OPRK1 3486/4885ALDH1A1 932/4885 |
| US-20030187061-A1 | Antitumor agnets; antileukemia agents | MCL1, TP53, EWSR1 | NPSR1 2717/4885OPRK1 3586/4885ALDH1A1 2220/4885 |
| US-20020147335-A1 | Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them | TOP2A, TOP2B, TUBB3 | NPSR1 3091/4885OPRK1 1334/4885ALDH1A1 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.